Few trials exist regarding the antiemetic efficacy of granisetron in bone marrow transplant (BMT) recipients conditioned with high-dose chemotherapy and total body irradiation (TBI). In this single-center, open-label, prospective, trial, the antiemetic efficacy and safety of granisetron plus dexamethasone were evaluated in 26 patients conditioned with cyclophosphamide-containing regimens (the majority receiving 60 mg/kg per day on 2 consecutive days), and TBI (12 Gy divided over 4 days). Daily intravenous doses of granisetron 1 mg plus dexamethasone 10 mg were given 30 min prior to chemotherapy or radiation, and continued for 24 h after the last conditioning treatment for a median of 6 days (range 3-9). Emetic control was defined by the number of emetic episodes occurring within a 24 h period, or the requirement for rescue medication for nausea or vomiting. A total of 25 patients completed 186 evaluable treatment days. Response (emetic control by treatment days) was complete in 50% of patients, major in 48%, minor in 2%, and there were no failures. Adverse effects were minor, with diarrhea (15%), headache (14%), and constipation (11%) reported most often. Based on these results, the antiemetic regimen of granisetron plus dexamethasone appears effective and well tolerated during BMT conditioning with high-dose cyclophosphamide and TBI. Keywords: granisetron; total body irradiation; bone marrow transplantation; antiemetic; vomiting; emesis Patients undergoing bone marrow transplantation (BMT) are often conditioned with regimens containing total body irradiation (TBI) and high-dose cyclophosphamide (alone or in combination with other chemotherapy agents). These regimens are highly emetogenic.
Patients undergoing bone marrow transplantation (BMT) are often conditioned with regimens containing total body irradiation (TBI) and high-dose cyclophosphamide (alone or in combination with other chemotherapy agents). These regimens are highly emetogenic.
1 Nausea and vomiting are among the most serious concerns to patients and physicians, impacting upon quality of life and continuation of therapy. 2 The development of 5-HT 3 -receptor antagonists has dramatically improved control of nausea and vomiting associated with chemotherapy [3] [4] [5] and radiation therapy. 6, 7 ever, the optimal dose and the dosing frequency of 5-HT 3 -receptor antagonists in patients receiving highly emetogenic chemotherapy and/or TBI prior to bone marrow or stem cell transplantation have yet to be determined, although studies have been conducted in these populations. [8] [9] [10] [11] [12] Enterochromaffin cells in the gastrointestinal mucosa release serotonin following administration of chemotherapy or radiation. [13] [14] [15] Serotonin has crucial roles in activating vagal (and possibly splanchnic) afferent neurons in the periphery and is involved centrally in the chemoreceptor trigger zone, which stimulates the vomiting reflex. Granisetron is a potent and selective 5-HT 3 -receptor antagonist that acts primarily at peripheral sites (eg, abdominal afferents) and possibly at central sites (eg, the chemoreceptor trigger zone, nucleus tractus solaris) to inhibit serotonin stimulation, thereby controlling nausea and emesis. [16] [17] [18] Both oral and intravenous granisetron are approved for the prevention of nausea and vomiting associated with initial and repeated courses of emetogenic cancer chemotherapy, including highly emetogenic chemotherapy. 19 Granisetron also has been reported to be effective in controlling radiationinduced nausea and vomiting, although this is not an approved indication in the United States. 6, 9, 20 Reducing the incidence of nausea and vomiting in bone marrow transplant (BMT) recipients receiving conditioning therapy offers the potential to enhance patient quality of life and reduce morbidity. Because conventional antiemetics have not produced optimal control, this prospective trial was designed to evaluate the emetic control rate and adverse effects of a combination of granisetron plus dexamethasone in BMT recipients receiving conditioning with TBI and high-dose cyclophosphamide-containing regimens.
Patients and methods

Patients
This single-center, open-label, prospective, trial was approved by the Institutional Review Board at MD Anderson Cancer Center, and written informed consent was obtained from all patients. Patients conditioned with a regimen of cyclophosphamide у60 mg/kg and receiving TBI a total of 12 Gy prior to BMT were eligible for inclusion in the study. Other inclusion criteria were age у16 years with a life expectancy of at least 8 weeks and performance status р2 on the Zubrod scale, ability to record perceptions of nausea and emetic episodes, and no acute central nervous system disease. Patients with diabetes mellitus were ineligible for this study.
Antiemetic therapy
Granisetron and dexamethasone were selected because of the clinical improvement in control of nausea and vomiting noted with this particular combination in patients receiving highly emetogenic chemotherapy at our institution. In the treatment sequence, high-dose chemotherapy was initiated and completed before TBI was administered. Granisetron 1 mg was infused by intravenous piggyback (IVPB) over 15 min, followed by dexamethasone 10 mg IVPB; both drugs were administered daily 30 min prior to the first dose of chemotherapy or radiation and continued for 24 h after the last dose of chemotherapy or radiation. If nausea was not controlled, an additional dose of granisetron 1 mg IVPB was permitted once per 24 h as rescue. If this was not effective or the patient requested that a different antiemetic be used, a combination of prochlorperazine 10 mg IVPB plus diphenhydramine 25 mg IVPB or lorazepam 2 mg IVPB, or a combination of haloperidol 2 mg IVPB plus diphenhydramine 25 mg IVPB was permitted every 4 h as needed for breakthrough nausea or vomiting.
Assessment of response
Each patient was provided with a diary, which was to be completed daily during chemotherapy and radiation and 24 h after the last conditioning therapy. Patients were asked to record their daily oral fluid intake and the number of vomiting episodes per day, rate nausea on a visual analog scale twice daily, and answer three questions concerning quality of life. The questions assessed daily routine and eating habits, compared the effectiveness of the current antiemetic regimen with previous experiences, and asked the patient to record any instance of unwanted effects, including headache, constipation, or diarrhea. All diary entries were compared with nursing documentation in the patient chart and verified.
Complete response was defined as no episodes of emesis in any 24 h period after the daily dose of granisetron and dexamethasone was administered, with no rescue antiemetics needed. Major response was defined as one or two emetic episodes, or the need for antiemetic rescue medication. A minor response was defined as three to five emetic episodes, and more than five emetic episodes was classified as failure. Patients were discontinued from the trial for unacceptable adverse effects, inadequate emetic control, or inability to complete the patient diary.
Results
Twenty-six patients were included in the trial, and 25 patients completed a total of 186 patient-days. One patient was excluded prior to starting therapy because she developed a migraine headache and vomiting and therefore was not evaluable. Three other patients voluntarily elected to be discontinued from the study on day 5 of therapy because of difficulty in maintaining a patient diary, but they were included in the efficacy and quality-of-life assessments and evaluation of toxicity on an intent-to-treat basis. The median age of patients was 40 years and the average weight was 77 kg. The majority of patients were female, and all had received prior emetogenic chemotherapy (Table  1) . Interestingly, more than half had no (42%) or mild (15%) nausea with prior chemotherapy. The majority of transplants were performed for leukemia or lymphoma, with most patients receiving a chemotherapy regimen of high-dose cyclophosphamide 60 mg/kg per day on days 1 and 3 then thiotepa 5 mg/kg on day 3 followed by TBI 3 Gy per day for 4 days. The median number of days on granisetron plus dexamethasone was 6 (range 3-9), and the mean oral fluid intake per day ranged from 1020 ml to 1480 ml ( Table 2) . Most patients were able to maintain adequate oral fluid intake during the trial.
Emetic control
A complete or major response to the combination of granisetron plus dexamethasone was observed in 98% of the 186 evaluable patient-days in the trial (Table 2 ). Complete emetic control was noted on 93/186 patient-days (50%), major responses were found on 89/186 (48%), minor responses on 4/186 (2%), and no failures were recorded. The number of patients experiencing emetic episodes ranged from 0 to 11 per day, with the number of emetic episodes ranging from 0 to 19. The emetic control rate by study day is shown in Figure 1 , which clearly shows that efficacy was sustained throughout the study. The number of antiemetic rescue doses administered each day is depicted in Figure 2 . Few patients required more than two doses of rescue medication in any 24-h period. The highest incidence of emesis and use of rescue antiemetics occurred on days 2 and 3 of the trial, but overall antiemetic response was complete or major for 96% of patients on these days.
Quality of life
The impact of granisetron plus dexamethasone on patient quality of life during the trial was significant (Table 3) total of 151 patient-days were evaluable for quality of life, and a majority of patients (65%) were able to maintain their daily routine and eating habits. These results are paralleled by the patients' responses assessing the effectiveness of their antiemetic medication. Ratings of 'very effective' were recorded on 64% of patient-days, 'somewhat effective' on 31%, and 'not effective' on 5%. Adverse effects recorded during the trial were minimal, with diarrhea (15%), headache (14%), and constipation (11%) reported most frequently.
Discussion
Many conditioning regimens used for BMT recipients combine high-dose chemotherapy with irradiation. Both treatment modalities are highly emetogenic and few studies have evaluated the combined antiemetic efficacy of a 5-HT 3 -receptor antagonist and dexamethasone in this setting. This prospective trial was conducted to evaluate the emetic control rate and safety of granisetron plus dexamethasone in BMT recipients conditioned with high-dose cyclophosphamide-containing regimens and TBI. The emetic control rate (complete response plus major response for total patient-days) was 98%, and no failures were recorded during the trial. Adverse effects were minimal, with diarrhea (15%), headache (14%), and constipation (11%) occurring most often. The complete response rate observed with granisetron and dexamethasone in this trial compares favorably with other published reports evaluating the antiemetic efficacy of 5-HT 3 -receptor antagonists during BMT conditioning. Granisetron as a single agent has been reported to be effective in controlling nausea and vomiting associated with high-dose chemotherapy with or without irradiation prior to BMT. 6, 9, 20, 21 In a comparable study, Okamoto and colleagues 21 evaluated the antiemetic efficacy of intravenous granisetron during conditioning therapy with high-dose chemotherapy or TBI prior to stem cell transplantation. The BMT ϭ bone marrow transplant; TBI ϭ total body irradiation.
complete response rate for emetic control by total patientdays was 54.9% in granisetron recipients, regardless of whether they were receiving high-dose chemotherapy or TBI. Similar results were observed when intravenous granisetron was used to prevent radiation-induced emesis in patients undergoing TBI prior to bone marrow transplantation. 9 Investigators in this study found the complete response rate to be 50% during TBI, and 75% during the 12 h following TBI. Hunter and her group 20 and Prentice and colleagues 6 also evaluated the antiemetic efficacy of intravenous granisetron during TBI in two similar studies. Patients evaluated in both were BMT recipients conditioned with high-dose chemotherapy followed by TBI. Both Hunter and Prentice described total emetic control during the 24 h after TBI in 56.3% and 53% of patients, respectively. However, the current trial differs from those reported above, with respect to duration (up to 9 days) and conditioning regimen.
Other 5-HT 3 -receptor antagonists (eg, ondansetron, dolasetron) have been examined for antiemetic efficacy in the BMT setting. 8, 11, 12, 22 In the most recently reported study, oral dolasetron was administered to BMT recipients conditioned with 3 days of TBI followed by 2 days of highdose cyclophosphamide. 11 The total emetic control rate during TBI was reported to be 55%, but control of emesis dropped off significantly during the subsequent 2 days of high-dose cyclophosphamide, with 33% of subjects experiencing none to two emetic episodes (complete or major response) by the last day of treatment.
The impact of antiemetic therapy on patient quality of life during BMT conditioning has not been widely reported. Maintaining adequate quality of life during the process of bone marrow transplantation is of major importance to patients and physicians. The experience of nausea and vomiting can affect the willingness of the patient to comply with therapy in the BMT setting. 22 In the present trial, patients were asked to complete a daily diary that assessed symptoms and daily activities (ie, eating, ambulating). The majority of patients (65%) indicated that they were able to eat and get out of bed without problems, with only 4% reporting emesis significant enough to keep them in bed most of the day. Patients also compared the antiemetic regimen of granisetron plus dexamethasone to previous antiemetic and chemotherapy experiences and 64% rated this regimen as very effective. Positive quality-of-life assessments were provided by 95% of patients during the trial, indicating that nausea or emesis did not significantly interfere with daily activities.
In conclusion, based on the results of this trial, the antiemetic regimen of granisetron plus dexamethasone appears to be effective and well tolerated during BMT conditioning with high-dose cyclophosphamide-containing regimens and TBI. Acceptable patient quality of life was maintained and
